GlassScriptPhysician profile
Rachel Reaume
NPI 1144787615
$4,371.96
in general payments reported to CMS, 2019-2025
26 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $440 · 2022: $680 · 2023: $1,000 · 2024: $823 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,117 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,116.90 |
| Education | $134.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,234.80 | 2021-2025 | |
| Janssen Biotech, INC. | $1,149.93 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $406.72 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.37 | 2022-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $180.90 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $108.16 | 2024-2025 | Vowst, Zenpep |
| Intercept Pharmaceuticals, INC. | $107.82 | 2023-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $101.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $88.14 | 2021-2022 | |
| Gilead Sciences, INC. | $84.75 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $73.19 | 2021 | |
| Qol Medical, LLC | $67.62 | 2023-2024 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $65.17 | 2022-2023 | Injectafer |
| Celgene Corporation | $60.15 | 2023-2024 | Zeposia |
| Pfizer INC. | $52.08 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $46.64 | 2023 | |
| Evoke Pharma, INC. | $46.12 | 2022-2024 | |
| Lilly USA, LLC | $44.62 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $44.42 | 2022-2023 | Dificid |
| Exact Sciences Corporation | $24.64 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $21.54 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $19.21 | 2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.16 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $13.84 | 2025 | Iqirvo |
| Vivus LLC | $12.29 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Reaume listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.